독서리서치레이더투자 프레임워크
로그인 / 회원가입
← 읽기로 돌아가기
뉴스주제 · Pathos AI중대1 분 소요DisconfirmAI 편집부

Bristol Myers Squibb leads $237M investment in AI drug development startup Pathos AI

US-based AI drug development startup Pathos AI has closed a $237 million Series E funding round at a valuation of approximately $3 billion. The round was led by pharmaceutical giant Bristol Myers Squibb, with participation from other existing investors.

검증됨 2026-10-24 04:09 GMT+8

US-based AI drug development startup Pathos AI announced on October 23, 2026, that it has closed a $237 million Series E funding round at a post-money valuation of approximately $3 billion. The round was led by pharmaceutical giant Bristol Myers Squibb, with participation from other existing investors.

Pathos AI is developing an artificial intelligence platform called Foundry, which uses thousands of specialized AI agents to aggregate clinical data, genomics and competitive landscape information in real time to identify promising drug molecules and plan clinical trials. The company stated that the new capital will primarily finance its key priority, the JSKN016 cancer therapy program, along with three other drug initiatives.

The investment is part of a broader strategic collaboration between Pathos AI, Bristol Myers Squibb, and Tempus AI. Under the agreement, Pathos AI will pay Tempus AI $55 million over five years to license anonymized patient data related to neurological conditions. This data will be analyzed using Foundry to help Bristol Myers Squibb improve its clinical trial designs and patient identification.

출처

로그인 / 회원가입
독서리서치레이더투자 프레임워크
pathos.com
↗
주제

Pathos AI

AI制药公司Pathos AI于2026年10月宣布完成2.37亿美元E轮融资,由美国百时美施贵宝(Bristol Myers Squibb)领投,估值达30亿美元。资金将用于扩展其Foundry人工智能平台,并加速包括TROP2/HER3…

2 단계1 건업데이트됨 2026-10-25 03:38

현재까지의 과정

  1. 2026-08-04Pathos AI与阿斯利康签署合作及共同独家许可协议,负责ER+/HER2-乳腺癌药物AZD4241的早期临床开发。pathos.com ↗
  2. 2026-10-23Pathos AI宣布完成2.37亿美元E轮融资,由百时美施贵宝领投,估值约30亿美元;同时宣布与百时美施贵宝、Tempus AI建立神经科学领域战略合作。siliconangle.com ↗

아직 해결되지 않은 문제

  • JSKN016启动注册性临床试验的具体时间表及预期入组规模。
  • Pathos Foundry平台在神经退行性疾病中的预测模型准确率是否达到监管要求。
  • 除已披露的合作伙伴外,其他现有投资者在E轮中的具体参与比例。
전체 주제 읽기 →
리서치 계속하기 →